इरिनोटेकन और रिफैम्पिसिन का इंटरैक्शन

Doxycycline Administered with rifampin (10 mg/kg daily) Decrease exposure Irinotecan Administered with an antibiotic regimen including rifampin (450 mg/day), isoniazid (300 mg/day), and streptomycin (0.5 g/day) IM Prevention or Management: Avoid the use of rifampin, a strong CYP3A4 inducer, if possible.

Substitute non-enzyme inducing therapies at least 2 weeks prior to initiation of irinotecan therapy Decrease irinotecan and active metabolite exposure Levothyroxine Decrease exposure Losartan Parent Decrease AUC by 30% Active metabolite (E3174) Decrease AUC by 40% Methadone In patients well-stabilized on methadone, concomitant administration of rifampin resulted…

• Strong CYP3A4 Inducers: Do not administer strong CYP3A4 inducers with CAMPTOSAR.

Do not administer strong CYP3A4 inducers with CAMPTOSAR unless there are no therapeutic alternatives.

The appropriate starting dose for patients taking these or other strong inducers such as rifampin and rifabutin has not been defined.

Strong CYP3A4 Inducers Exposure to irinotecan or its active metabolite SN-38 is substantially reduced in adult and pediatric patients concomitantly receiving the CYP3A4 enzyme-inducing anticonvulsants phenytoin, phenobarbital, carbamazepine, or St.

Consider substituting non-enzyme inducing therapies at least 2 weeks prior to initiation of CAMPTOSAR therapy.